IBEX Turns AI From Threat to Growth Engine — and the Tape Already Knows

A $418M BPO outsourcer up 33% in 90 days is monetizing agentic AI while the infrastructure basket it supposedly threatens gets de-rated

IBEX · Earnings Call · 2026-09-10

A small-cap riding a wave the rest of AI is drowning in

IBEX Limited reported fiscal Q4 and full-year 2026 on September 10 from a position of strength: the stock is up 33.4% over the last 90 trading days and sits within 5.5% of its September 3 record close of $39.41, versus a $418M market cap. That is a rare tape for this quarter. Look at the global 30-day decliner list and you find growth in data centers and adjacent high-performance compute names getting de-rated hard — a broad basket of 50-plus infrastructure tickers negative on the month, with data center capacity down on both the 90-day and 30-day windows. IBEX is an IT services company that monetizes AI adoption rather than a capex-heavy hardware proxy, and the two tapes are diverging cleanly. The bigger contrast is thematic. The loudest fresh theme across this quarter's reporters is Tariff refunds — ASO, AEO, CULP, DBI, JILL, LAKE, M and VNCE all leaned on IEEPA recoveries. IBEX has none of that. Its story is entirely company-unique.

What actually changed: from pilot to production

The word traditional BPO spent the year as IBEX's framing device, but the telling new cluster is AI agent solution — now a top-three keyword for the company, sitting alongside Sierra AI and proof of concept. AI has been an IBEX keyword for roughly two years, so the theme itself is not new; what is new is that management converted it from aspiration into named case studies with numbers.

Importantly, we have now turned the perceived threat of AI for BPOs into an important growth opportunity for IBEX.
Robert T. Dechant, CEO · 2026-09-10

The proof points: Philippine Airlines won against a pure-play AI vendor, a SaaS vendor and a traditional BPO peer, with resolution rates above 20% and CSAT above 4.7; BJ's Wholesale hit 40%-plus resolution and is now expanding into human agents. Management says it has "double digit client deployments with our AI agent solutions spread across 5 verticals." The prior-quarter call flagged the risk explicitly — “It will cannibalize some of our business as human volume gets displaced by AI, but if we have that solution in place... the model says it will be accretive for revenue.” — Bob Dechant, CEO · 2026-05-06 The Q4 evidence is the first real test of that arithmetic, and it passed. Note the client win engine: “we added 9 new trophy logos, bringing our annual total to 17 wins across multiple verticals and geographies.” — Robert T. Dechant, CEO · 2026-09-10 The global read-through is favorable. The agentic theme is broad this quarter — ADBE's agentic software, ORCL's Agentic Studio, SAIL's Agentic Suites, TIG.L's agentic AI — so IBEX is riding a real wave rather than inventing one. It is doing so as a services integrator, not a model builder. “we truly believe we future proof this business.” — Robert T. Dechant, CEO · 2026-09-10

Health tech cleared its own goal

The most concrete financial change is the health tech vertical, up 42% in Q4 and 38% for the year to $114M — comfortably past the $100M target management set a year ago. That vertical now runs at roughly 18% of revenue. Revenue quality is strong: top-5 and top-10 clients grew 24% and 22%, client retention is above 99%, client NPS 71, and employee NPS rose from 77 to 82. Reflecting the operating leverage, net profit margin has climbed to 8.1%, up 0.6pp year over year, while operating margin sits at 9.8%, +0.4pp. The stock, though, still trades like a low-margin labor outsourcer: price-to-revenue is 0.6x, down 13% over three years and price-to-net-income is 7.6x. That gap is the whole investment case.

Where the story gets shakier: margins and the decelerating guide

Q4 adjusted EBITDA margin slipped to 12.3% from 13.9%, hit by new-client training costs, a $2M nearshore-to-offshore restructuring charge, and higher fuel costs in offshore utilities. Management was explicit: “We expect adjusted EBITDA margins to return to expanding in the first quarter of fiscal year 27.” — Taylor C. Greenwald, CFO · 2026-09-10 The balance sheet backs that up, with net cash improving $17.2M to $30.9M and a revolver renewed to 2029 — a welcome reversal for a company whose effective net cash had drawn down 69% from its $62M peak. The wobble is guidance. FY27 revenue is guided to $700–715M, or 9–11% growth, versus the 15.4% organic rate just delivered. Bearish read: the AI wave is not yet large enough to stop the headline number from slowing. Bullish read: “we are providing initial first quarter and fiscal year 27 revenue and adjusted EBITDA guidance” — Taylor C. Greenwald, CFO · 2026-09-10 that still implies EBITDA accelerating 9–14%. The clean tell is that a year ago management was candid that AI was “not moving the needle on a whole lot of revenue and margin expansion yet, but we're positioned well.” — Robert Dechant, CEO · 2025-11-07 Now it claims the needle is moving. Reconciling those two statements is precisely the work the next two quarters will do.